In a report released on September 24, Mani Foroohar from Leerink Partners maintained a Hold rating on Bluebird Bio (BLUE – Research ...

Ensysce Biosciences, Inc. ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and ...

The board of directors today declared a quarterly dividend of $0.2775 per share on the company's common shares, payable November 1, 2024. Key Takeaways: The board of directors declared a quarterly ...

SOMERVILLE, Mass. (AP) — SOMERVILLE, Mass. (AP) — Bluebird Bio Inc. (BLUE) on Friday reported a loss of $81.4 million in its second quarter. The Somerville, Massachusetts-based company said it had a ...

SOMERVILLE, Mass., September 27, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the "Q2 2024 Form 10-Q") ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

On Thursday, bluebird bio Inc (BLUE) stock saw a modest uptick, ending the day at $0.5 which represents a slight increase of $0.02 or 4.17% from the prior close of $0.48. The stock opened at $0.51 and ...

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...

Gene therapy for sickle cell disease remains a tough business model — and may never work, @adamfeuerstein writes.

截至6月底，bluebird bio拥有375名全职员工，本次裁员意味着将有近百名员工离开公司。 其实，在宣布裁员前，bluebird bio 就在其延迟的年度证券申报中预告，其可能没有足够的财务资源来继续运营一年。截至今年6月底，bluebird ...